title: Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
abstract: The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.
authors.affiliation: University of Wisconsin Clinical Cancer Center, Madison 53792.
authors.forename: H I
authors.initials: HI
authors.lastname: Robins
authors.forename: D S
authors.initials: DS
authors.lastname: Neuberg
authors.forename: A B
authors.initials: AB
authors.lastname: Benson
authors.forename: K J
authors.initials: KJ
authors.lastname: Pandya
authors.forename: D C
authors.initials: DC
authors.lastname: Tormey
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D007191:Indazoles; C016371:lonidamine